Followers | 189 |
Posts | 33239 |
Boards Moderated | 4 |
Alias Born | 08/30/2018 |
Wednesday, October 18, 2023 9:54:42 AM
Recent ICU News
- The Gross Law Firm Notifies SeaStar Medical Holding Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 08/08/2024 09:45:00 AM
- Class Action Filed Against SeaStar Medical Holding Corporation (ICU) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 08/05/2024 09:45:00 AM
- Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s • GlobeNewswire Inc. • 07/26/2024 01:00:00 PM
- First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device • GlobeNewswire Inc. • 07/23/2024 12:30:00 PM
- Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children’s • GlobeNewswire Inc. • 07/17/2024 01:00:00 PM
- CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial • GlobeNewswire Inc. • 07/16/2024 12:30:00 PM
- Edelson Lechtzin LLP Urges SeaStar Medical Holding Corporation (NASDAQ: ICU, ICUCW) Shareholders to Consult Legal Counsel About the Pending Securities Fraud Class Action • PR Newswire (US) • 07/12/2024 09:05:00 PM
- SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner • GlobeNewswire Inc. • 07/12/2024 12:30:00 PM
- SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 07/11/2024 08:05:00 PM
- SeaStar Medical Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 07/10/2024 01:00:00 PM
- SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device • GlobeNewswire Inc. • 07/03/2024 12:30:00 PM
- SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology • GlobeNewswire Inc. • 06/11/2024 12:30:00 PM
- SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company • GlobeNewswire Inc. • 06/10/2024 12:30:00 PM
- Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation • GlobeNewswire Inc. • 06/07/2024 12:30:00 PM
- SeaStar Medical Announces 25-for-1 Reverse Stock Split • GlobeNewswire Inc. • 06/06/2024 12:30:00 PM
- Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility • GlobeNewswire Inc. • 05/22/2024 12:30:00 PM
- SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 05/14/2024 08:05:00 PM
- SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure • GlobeNewswire Inc. • 04/30/2024 12:30:00 PM
- SeaStar Medical Reports 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 04/17/2024 08:00:00 PM
- SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 12:30:00 PM
- SeaStar Medical to Restate Financials, Sets Business Update Call for April 17 • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients • GlobeNewswire Inc. • 03/12/2024 12:30:00 PM
- SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024 • GlobeNewswire Inc. • 03/11/2024 08:05:00 PM
- Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™ • GlobeNewswire Inc. • 02/22/2024 12:58:00 PM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM